Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

NCT02251717 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02251717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02251717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
October 14, 2014
Completion date
June 16, 2016
Enrollment
114 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection